CLINICAL RESEARCH: VALVULAR HEART DISEASE
Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis
Martin Briand, MS*,1,
Isabelle Lemieux, PhD*,
Jean G. Dumesnil, MD, FACC*,
Patrick Mathieu, MD*,
Amélie Cartier, MS*,
Jean-Pierre Després, PhD, FAHA*, ,3,
Marie Arsenault, MD*,4,
Jacques Couet, PhD*,4 and
Philippe Pibarot, DVM, PhD, FACC*,2,*
* Laval Hospital Research Center/Québec Heart Institute, Department of Medicine, Laval University, Québec, Canada
Division of Kinesiology, Department of Social and Preventive Medicine, Laval University, Québec, Canada
Manuscript received September 7, 2005;
revised manuscript received December 19, 2005,
accepted December 30, 2005.
* Reprint requests and correspondence: Dr. Philippe Pibarot, Laval Hospital Research Center, 2725 Chemin Sainte-Foy, Sainte-Foy, Quebec, Canada, G1V-4G5. (Email: philippe.pibarot{at}med.ulaval.ca).
OBJECTIVES: This study sought to examine the association between the metabolic syndrome (MS) and the progression of aortic stenosis (AS).
BACKGROUND: It has been suggested that aortic valve sclerosis and its progression to AS are caused by an atherosclerotic process. Metabolic syndrome is associated with a higher risk of vascular atherosclerosis. Thus, we hypothesized that the atherogenic features of MS could negatively influence disease progression and prognosis in patients with AS.
METHODS: We retrospectively analyzed the data of 105 consecutive patients (age 69 ± 12 years, 64 men) with at least moderate AS. Of these patients, 40 (38%) had MS identified according to the modified clinical criteria proposed by the National Cholesterol Education Program-Adult Treatment Panel III. The hemodynamic progression of AS was assessed by the measurement of the annualized decrease in valve area during the follow-up period of the study, which averaged 28 ± 13 months. Event-free survival was defined as the absence of death or aortic valve replacement during follow-up.
RESULTS: The hemodynamic progression of the stenosis was twice as fast (–0.14 ± 0.13 cm2/year vs. –0.08 ± 0.08 cm2/year, p = 0.008) and the three-year event-free survival was markedly lower (44 ± 8% vs. 69 ± 6%, p = 0.002) among patients with MS. In multivariate analysis, MS was found to be a strong independent predictor of both stenosis progression (p = 0.006) and event-free survival (odds ratio 3.85, 95% CI 1.96 to 7.58, p < 0.001).
CONCLUSIONS: The present study is the first to report that MS is associated with a faster disease progression and worse outcome in patients with AS. Such findings open new avenues of research and provide a strong impetus for the elaboration of additional prospective studies focusing on this association.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | AS = aortic stenosis | | AVA = aortic valve area | | AVR = aortic valve replacement | | CRP = C-reactive protein | | HDL = high-density lipoprotein | | LDL = low-density lipoprotein | | MS = metabolic syndrome | | NCEP-ATPIII = National Cholesterol Education Program-Adult Treatment Panel III |
|
This article has been cited by other articles:
|
|
|
|
 
P Mathieu, P Pibarot, and J-P Despres
Heart,
June 1, 2009;
95(11):
938 - 939.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Akat, M Borggrefe, and J J Kaden
Aortic valve calcification: basic science to clinical practice
Heart,
April 1, 2009;
95(8):
616 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Katz, M. J. Budoff, J. Takasu, D. M. Shavelle, A. Bertoni, R. S. Blumenthal, P. Ouyang, N. D. Wong, and K. D. O'Brien
Relationship of Metabolic Syndrome With Incident Aortic Valve Calcium and Aortic Valve Calcium Progression: The Multi-Ethnic Study of Atherosclerosis (MESA)
Diabetes,
April 1, 2009;
58(4):
813 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Parolari, C. Loardi, L. Mussoni, L. Cavallotti, M. Camera, P. Biglioli, E. Tremoli, and F. Alamanni
Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention
Eur. J. Cardiothorac. Surg.,
March 1, 2009;
35(3):
493 - 504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Rajamannan
Calcific Aortic Stenosis: Lessons Learned From Experimental and Clinical Studies
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2009;
29(2):
162 - 168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Cote, P Pibarot, J-P Despres, D Mohty, A Cartier, B J Arsenault, C Couture, and P Mathieu
Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis
Heart,
September 1, 2008;
94(9):
1175 - 1180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Helske, T. Miettinen, H. Gylling, M. Mayranpaa, J. Lommi, H. Turto, K. Werkkala, M. Kupari, and P. T. Kovanen
Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves
J. Lipid Res.,
July 1, 2008;
49(7):
1511 - 1518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Owens, R. Katz, E. Johnson, D. M. Shavelle, J. L. Probstfield, J. Takasu, J. R. Crouse, J. J. Carr, R. Kronmal, M. J. Budoff, et al.
Interaction of Age With Lipoproteins as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis
Arch Intern Med,
June 9, 2008;
168(11):
1200 - 1207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Bosse, P. Mathieu, and P. Pibarot
Genomics: The Next Step to Elucidate the Etiology of Calcific Aortic Valve Stenosis
J. Am. Coll. Cardiol.,
April 8, 2008;
51(14):
1327 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mohty, P. Pibarot, J.-P. Despres, C. Cote, B. Arsenault, A. Cartier, P. Cosnay, C. Couture, and P. Mathieu
Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2008;
28(1):
187 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Rahimtoola
The Year in Valvular Heart Disease
J. Am. Coll. Cardiol.,
January 23, 2007;
49(3):
361 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Briand, P. Pibarot, J.-P. Despres, P. Voisine, J. G. Dumesnil, F. Dagenais, and P. Mathieu
Metabolic Syndrome Is Associated With Faster Degeneration of Bioprosthetic Valves
Circulation,
July 4, 2006;
114(1_suppl):
I-512 - I-517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
